Several studies appear to support plaintiffs arguments and raise more questions over the safety of new-generation anticoagulant drug Xarelto. The blood thinner is manufactured by Bayer Healthcare and Janssen Pharmaceuticals (a division of Johnson & Johnson corporation). These new studies highlight a potential link to spontaneous and severe bleeding episodes, including stomach bleeds and eye-hemorrhages for patients using Xarelto.
The first of two notable studies was completed by Doctors John C. Hwang and Judy H. Hun after they had observed certain problems experienced by patients in their practice involving those aged 70-89 who initially used traditional blood thinner warfarin, and had later switched to use new-generation blood thinner Xarelto. The doctors noticed that these individuals were increasingly suffering from vitreous hemorrhages, or eye bleeds. Further testing confirmed to the medical team that when patients switched blood thinners, they were at increased risk for this health issue to occur.
Eye bleeding incidents
The doctors carefully documented full medical evaluations of patients as they started to wean off of warfarin and begin Xarelto, and this is when they witnessed the most eye bleeding incidents. Their full reports on the bleeding events were published by JAMA Ophthalmology in their June, 2015 issue. As evaluated patients began to wean off of their traditional blood thinner (Warfarin), and switch over to Xarelto, this is when the bleeding incidences would occur. The doctor’s reports stated: “In all cases, an acute vitreous hemorrhage occurred shortly after rivaroxaban (Xarelto) treatment was initiated.” They were hopeful that their discoveries would prevent other patients from switching blood thinners and experiencing the same problem.
Another study that also lends support to current Xarelto lawsuit plaintiffs, was published in an April 2015 issue of BMJ. This study indicated researchers of the different types of blood thinners were unable to rule out as much as a twofold increased risk of stomach bleeding for those taking Xarelto when compared to those using Warfarin. This study evaluated the results of almost 46,000 patients to come to these conclusions.
If these results are in fact accurate, they greatly support the arguments of almost 2,800 plaintiffs who have filed lawsuits against Xarelto manufacturers alleging that the blood thinner caused them dangerous and uncontrollable bleeding episodes, and, in some cases, that these episodes were fatal. Federally filed Xarelto lawsuits have been consolidated by the U.S. Judicial Panel on Multidistrict Litigation (JPML) to form MDL No. 2592. They are being overseen by Judge Eldon Fallon in New Orleans, Louisiana.
Attorney Joseph Osborne is working to help ensure that everyone who has taken Xarelto and who has also suffered from serious side effects will have the opportunity to evaluate their full legal rights. It is possible for additional lawsuits to join the current MDL as the cases await further legal proceedings. Attorney Osborne is now offering free Xarelto consultations to affected individuals, who may be entitled to substantial compensation.